A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
by on Wednesday, April 25th, 2012 | No Comments
Condition: Melanoma
Interventions: Drug: dabrafenib plus trametinib; Drug: dabrafenib plus trametinib placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting – verified April 2012
See more here: A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma